Chest Pain

Disease

Related News

Mavacamten Shows Promise for Adolescents with Hypertrophic Cardiomyopathy

Mavacamten significantly reduces heart obstruction in adolescents with hypertrophic cardiomyopathy, with patients experiencing a 48.5 mm Hg drop in blockage compared to minimal change in placebo groups. The drug also lowered blood markers indicating heart damage and showed promise in slowing disease progression. Separate real-world data confirms mavacamten's effectiveness as monotherapy across diverse patient populations.

Related Clinical Trials

NCT ID Title Status Phase
NCT07579182

Hormones, Outcomes, and Pain Pathways in Exercise Study

NOT_YET_RECRUITING PHASE1
NCT07536932

Triage and Recognition of Acute Aortic Dissection in Chest Pain by Electrocardiogram-Artificial Intelligence

NOT_YET_RECRUITING
NCT07532564

Risk Factors, Costs, and Impacts of ED Boarding

COMPLETED
NCT07435168

CHEST-CA: Study of Chest Pain and Hidden Cardiac Amyloidosis

RECRUITING NA
NCT07432620

Artificial Intelligence Stress Echo (FINESSE) Project

ACTIVE_NOT_RECRUITING
NCT07258290

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions

NOT_YET_RECRUITING NA
NCT07247669

Evaluation and Optimization of Telephone Triage Using Artificial Intelligence (AI) Models for the Detection of Demands for Time-dependent Pathology at the Emergency and Urgent Care Coordination Center (CCUE).

RECRUITING
NCT07235657

AI-Assisted Interpretation of Cardiac CT in the Emergency Department

NOT_YET_RECRUITING NA
NCT07192965

ECG-less Coronary Computed Tomography Angiography in the Management of Patients Presenting With High-troponin Chest Pain

RECRUITING NA
NCT07140419

Coronary Computed Tomographic Angiography Combined With CT-FFR in Intermediate-Risk Chest Pain Patients.

NOT_YET_RECRUITING NA